US Stocks, page 41 of 41 — 24 articles published 2026-05-14 ~ 2026-05-15.
ENPH Enphase Energy stock analysis for 2026. Microinverter market leader with IQ8 technology, IRA tailwinds, U.S. and European residential solar dynamics, SolarEdge competition, energy storage ecosystem, and bull/base/bear scenarios for growth investors.
CL Colgate-Palmolive Dividend King analysis for 2026. Global oral care market leader with 40% toothpaste share, Hill's Pet Nutrition growth engine, 45%+ emerging market revenue, pricing power versus P&G, and dividend sustainability assessment.
KMB Kimberly-Clark Dividend King analysis for 2026. Huggies, Cottonelle, Kleenex brand portfolio, emerging market growth strategy, P&G competitive dynamics, raw material cost cycles, and dividend sustainability for long-term income investors.
WBA Walgreens Boots Alliance stock analysis for 2026. Dividend cut context, VillageMD restructuring, PBM margin pressure, CVS competition, debt management, and bull/base/bear scenarios for dividend investors considering recovery plays.
BIDU Baidu stock outlook 2026: ERNIE large language model vs. ChatGPT, Apollo Go robotaxi commercial expansion, ACE cloud AI services, Chinese search revenue pressure, VIE structure, HFCAA risk, and scenario analysis for US investors.
PDD Holdings stock outlook 2026: Temu global expansion risk, US de minimis tariff changes, Pinduoduo China e-commerce competition with Alibaba, VIE structure, HFCAA, and bull/base/bear scenarios for US investors.
Li Auto LI stock outlook 2026: EREV range-extender technology, Li MEGA pure EV pivot, profitability profile vs. NIO and XPeng, VIE structure, HFCAA risk, and scenario analysis for US retail investors.
XPEV XPeng stock outlook 2026: XNGP self-driving tech, Volkswagen strategic partnership revenue, MONA brand, VIE structure, HFCAA delisting risk, and bull/base/bear scenarios for US investors.
NIO stock outlook 2026: BaaS battery swap model, ONVO and Firefly multi-brand strategy, HFCAA delisting risk, VIE structure, bull/base/bear scenarios for US retail investors.
ASTS AST SpaceMobile 2026: Direct-to-Cell satellite, AT&T Verizon Vodafone MNO partners, BlueBird constellation, Starlink competition, risk scenarios.
COHR 2026: 800G/1.6T optical transceivers, II-VI merger synergies, AI data center demand, InP moat, and three investment scenarios.
MCHP 2026: industrial MCU inventory cycle, PIC/AVR ecosystem moat, Microsemi defense floor, dividend growth, and three investment scenarios.
CMG Chipotle 2026 outlook: fast-casual leader, Autocado automation, throughput strategy, Chipotlane drive-through, and MCD YUM WING scenario analysis.
Leidos LDOS 2026: DoD IT integration, JADC2, MHS GENESIS, cybersecurity, SAIC CACI BAH comparison, dividend, and bull/bear scenarios.
ON Semiconductor 2026: SiC power for EVs, automotive CIS, Wolfspeed opportunity, East Fishkill fab, LTSA backlog, and three investment scenarios.
NXPI 2026: automotive MCU cycle, S32 SDV platform, V2X tailwinds, Infineon comparison, and three investment scenarios for US investors.
AVAV 2026: Switchblade loitering munitions, Raven UAVs, Replicator Initiative, FMS pipeline, Anduril competition, and bull/bear investment scenarios.
ZS Zscaler 2026. Zero Trust SASE leader, PANW Cloudflare CRWD competition, federal mandate, AI security demand, ARR NRR and scenario analysis.
AFRM Affirm 2026 outlook: BNPL leader, Apple Pay and Shopify anchors, KLARNA PYPL competition, RLTC margin trends, and credit cycle scenario analysis.
LCID Lucid Motors 2026: Saudi PIF backing, Air and Gravity SUV, powertrain B2B optionality, dilution risk, RIVN TSLA comparison, bull/bear scenarios.
CRSP CRISPR Therapeutics 2026. Casgevy CRISPR therapy, BEAM NTLA BLUE competition, CAR-T pipeline, and commercialization scenarios for investors.
QS QuantumScape 2026: ceramic separator solid-state battery, VW Power Co milestones, SLDP Toyota competition, dilution risk and bull/bear scenarios.
IonQ (IONQ) 2026 stock analysis: trapped-ion vs superconducting, AWS Braket and Azure Quantum partnerships, dilution risk, and bull/bear scenarios.
VKTX Viking Therapeutics 2026. VK2735 obesity Phase 3, oral GLP-1 race vs LLY NVO, VK0214 X-ALD pipeline, M&A optionality and clinical scenarios.